Atara Biotherapeutics (ATRA) Leases (2022 - 2025)
Historic Leases for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $10.7 million.
- Atara Biotherapeutics' Leases fell 7663.91% to $10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.7 million, marking a year-over-year decrease of 7663.91%. This contributed to the annual value of $39.8 million for FY2024, which is 2753.8% down from last year.
- Atara Biotherapeutics' Leases amounted to $10.7 million in Q3 2025, which was down 7663.91% from $11.0 million recorded in Q2 2025.
- In the past 5 years, Atara Biotherapeutics' Leases ranged from a high of $73.6 million in Q2 2022 and a low of $10.7 million during Q3 2025
- Over the past 4 years, Atara Biotherapeutics' median Leases value was $52.0 million (recorded in 2024), while the average stood at $48.8 million.
- As far as peak fluctuations go, Atara Biotherapeutics' Leases skyrocketed by 24407.12% in 2023, and later tumbled by 7747.2% in 2025.
- Over the past 4 years, Atara Biotherapeutics' Leases (Quarter) stood at $68.0 million in 2022, then fell by 19.24% to $54.9 million in 2023, then fell by 27.54% to $39.8 million in 2024, then plummeted by 73.1% to $10.7 million in 2025.
- Its Leases stands at $10.7 million for Q3 2025, versus $11.0 million for Q2 2025 and $50.8 million for Q1 2025.